COLOGNE, MARBURG, BRAUNSCHWEIG & INGELHEIM, Germany-Friday 18 December 2020 [ AETOS Wire ]
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim collaborate on potential COVID-19 therapy and prevention
BI 767551 (DZIF-10c) is a potent anti-SARS-CoV-2 antibody that has shown promising virus neutralizing properties in pre-clinical research
Phase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled
(BUSINESS WIRE) -- Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF’s expertise in virology, immunology and clinical investigation with Boehringer Ingelheim’s expertise in developing and manufacturing therapeutic antibodies, the partners developed BI 767551 as a potential new therapeutic and preventive/prophylactic option for fighting COVID-19.
Virus neutralizing antibodies are expected to become an important line of defense against SARS-CoV-2, complementing vaccines and nonpharmaceutical interventions. They are being investigated as a therapy option for individuals with mild or severe infections, but also as prevention or prophylaxis in non-infected people with a high risk of infection or at risk of serious outcomes. Directly delivering BI 767551 to the lung by inhalation has the potential to provide fast acting protection from virus infection in the respiratory tract.
The new antibody BI 767551 was derived from blood samples of recovered COVID-19 patients at UKK, examined for SARS-CoV-2 neutralization at UMR and developed further in collaboration with Boehringer Ingelheim. The clinical study will be led by Prof. Florian Klein and Prof. Gerd Fätkenheuer at UKK and Boehringer Ingelheim will supply the antibody. “With BI 767551, we aim to provide an effective option for preventing and treating COVID-19,” explains Prof. Florian Klein, Director of the Institute for Virology at the Cologne University Hospital and Principal Investigator at the DZIF.
”Monoclonal antibodies are a promising component in the fight against new viruses, such as the SARS-CoV-2. If this antibody turns out to be effective against COVID-19, this finding could be helpful in the current and also in future epidemics and pandemics. I am glad that we are able to assist in the development of this compound," says Prof. Stephan Becker, Director of the Institute of Virology at University of Marburg and Coordinator Emerging Infections, DZIF.
“We are excited to contribute to the development of BI 767551 in collaboration with our partners, with the aim to provide an innovative SARS-CoV-2 neutralizing antibody, combining a systemic with an inhaled route of administration” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit.
The Phase 1/2a studies (NCT04631705, NCT04631666) will evaluate the safety, pharmacokinetics and antiviral activity of the antibody. In Phase 1, the antibody will be administered to participants either with a single infusion or a single inhalation. If the antibody is well tolerated, late-stage confirmatory studies will be conducted.
Please click on the following link for ‘Notes to Editors’:
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005318/en/
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
Cologne University Hospital (UKK)
Tel.: +49 (221) 478 88757
University of Marburg (UMR)
Dr. Gabriele Neumann
Leiterin der Stabsstelle Hochschulkommunikation
Tel.: +49 6421 28-26118
German Center for Infection Research (DZIF)
Karola Neubert und Janna Schmidt
Tel. : +49 6181 1170/1154
Permalink : https://www.aetoswire.com/news/new-sars-cov-2-neutralizing-antibody-enters-clinical-phase/en
Post a Comment